Seeyond’s 10x Genomics TXG Stock Holding History

Seeyond’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-839	Closed	-$37K	–	614
2022 Q2	$37K	Sell	839 -17	-2%	-$882	﹤0.01%	593
2022 Q1	$65K	Sell	856 -17	-2%	-$1.49K	0.01%	587
2021 Q4	$130K	Hold	873	–	–	0.01%	580
2021 Q3	$127K	Sell	873 -9	-1%	-$1.54K	0.01%	573
2021 Q2	$172K	Buy	882 +4	+0.5%	+$724	0.02%	549
2021 Q1	$158K	Hold	878	–	–	0.02%	567
2020 Q4	$124K	Buy	+878	New	+$127K	0.01%	590

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Seeyond's TXG Position: Q3 2022 in Review

Seeyond sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 839 shares — an estimated $37K sold.

Seeyond first reported a position in TXG in Q4 2020 and held it in 7 quarters. The position peaked at $172K in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

Seeyond reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
Seeyond sold 839 10x Genomics shares in Q3 2022, an estimated $37K.
Seeyond first reported a position in 10x Genomics in Q4 2020 and held it in 7 quarters.
Seeyond's 10x Genomics position peaked at $172K in Q2 2021.
233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Seeyond's 13F filing for Q3 2022, filed 14 Nov 2022.